Product Name: HIPK2 (1159-1176)
Product Number: PE-01BDD99
Size: 1 mg      Price:122.00
5 mg      $US266.00
20 mg      486.00
Peptide Name: HIPK2 (1159-1176)

Product Use: Services as a blocking peptide for use with the HIPK2-BCT rabbit polyclonal antibody (Cat. No.: AB-NK272-1) that is also available from Kinexus. The peptide sequence is located in the pre-C-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: HPSQYPAQFAHQTYISASC

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2135.3 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: HIPK2 pan-specific antibody (Cat. No.: AB-NK272-1)

Scientific Background: HIPK2 is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is believed to be involved in inducing apoptosis, through phosphorylation of p53, after genotoxic stress. It interacts with numerous transcription factors (such as p53, AML1(RUNX1), PAX6, c-MYB or NK3) as well as transcriptional regulators (such as CBP, p300, Groucho, CtBP, HMGA1 or Smads). In this way HIPK2 can activate or repress transcription and thereby influence differentiation, development and the DNA damage response. HIPK2 can promote the apoptotic program via p53-dependent and -independent pathways through phosphorylation of p53 at S46 or phosphorylation of the anti-apoptotic co-repressor CtBP at S422 (both actions leading to the transcription of pro-apoptotic target genes). HIPK2 may be an oncoprotein (OP) or a tumour suppressor protein (TSP). HIPK2 is upregulated in some cervical cancers, and down regulated in some thyroid and breast carcinomas. In most cancer systems appears to repress growth and prevent tumourigenesis. In cervical cancer was described to be upregulated but this may represent a compensation of normal cellular machinery.